Site Search

Here's what you need to know about the four CFTR (cystic fibrosis transmembrane conductance regulator) modulators.

The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.

For those of us without a medication that targets our cystic fibrosis mutation, it's important to remember that our life with CF is a marathon.

The CF Foundation is focused on bringing forward new therapies to help people with CF enjoy the best health and quality of life.